The latest industry headlines, news scoops, reviews, opinions, press releases, virus alerts, security updates, and other time-sensitive information.
Free registration required to read the story.”…The company, Avigen, said yesterday that it was ending the hemophilia trial so it could shift its strategic focus to neurological diseases. But it also said that the hemophilia therapy faced ‘certain scientific, regulatory and clinical hurdles.’ “
Are you an expert in one subject or another? If your goal is to help others and dispense your hard-earned information back to the community, get involved in our community site today! You can write about anything - no matter the topic. Exceptional candidates will be offered the chance to contribute to (and generate revenue from) the main Lockergnome site. Join us today!
65 queries / 0.188 seconds.